CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

Inclusion Criteria: * Must have histologically confirmed renal cell carcinoma of any pathologic subtype. * Must have unresectable metastatic disease, and have tumor(s) present that is (are) evaluable by the RECIST, v1.1; may have spinal-associated metastases but must have concluded dexamethasone therapy and be evaluated by the Investigator to have stable CNS disease. * Must have received 2 or 3 prior lines of conventional molecularly targeted therapy * Must have full recovery from any toxicities from prior therapy CTCAE Grade 1 or less with the exception of Grade 2 alopecia) prior to randomization. * ECOG performance status 0 or 1. * Age 18 years and older. * Life expectancy of at least 3 months. * Must have normal organ and marrow function reported within 14 days prior to randomization * Ability to understand and willingness to sign a written informed consent document. * Able to comply with study visit schedule and assessments. Exclusion Criteria: * Any conventional molecularly targeted therapy within 2 weeks or, chemotherapy or radiotherapy within 2 weeks (local) or 4 weeks (systemic) prior to entering the study. * Failure to recover to grade 1 or less all prior adverse events. * Any major surgery within 4 weeks of study randomization. * Any prior treatment with topoisomerase I therapy. * Prior treatment with any drugs or therapies that will be administered during the course of this trial including CRLX101, any topoisomerase 1 inhibitor, bevacizumab or the conventional molecularly targeted agent intended for use as standard of care treatment. * Patients receiving any other current investigational therapeutic agent. * Other active malignancies * Patients with brain metastasis treated or untreated, or other CNS disease * Any clinically significant cardiac disease defined as NYHA class III or IV. * Uncontrolled hypertension * Uncontrolled concurrent illness * History of non-healing wounds or ulcers. * Pregnancy, or inadequate contraception for men or women of childbearing age, or lactating / breast-feeding * Patients with known HIV or with solid organ transplant